Marcela Maus: Closing plenary to explore the future of CAR T-Cell therapy in solid tumors
Mediamedic posted on LinkedIn:
”Closing Plenary: The Future of CAR T-Cell Therapy in Solid Tumors
The final plenary of Tandem Meetings 2025, chaired by Dr. Marcela Maus (Massachusetts General Hospital Cancer Center, Harvard Medical School), explored the next frontier in cellular immunotherapy – expanding CAR T-cell therapy from hematologic cancers to solid tumors.
Speakers Dr. Saul Priceman (USC) and Dr. Julia Carnevale (UCSF) presented cutting-edge research on tumor microenvironment modulation, CRISPR-based functional genomics, and next-generation T-cell engineering aimed at overcoming T-cell exhaustion and antigen heterogeneity.
“This closing plenary offers an exciting glimpse into the future of cellular therapeutics,” said Dr. Maus. “We are united in improving the patient experience and curing disease by leveraging cells as medicine.” ”
Find more here.
Stay updated with Hemostasis Today.
-
Apr 11, 2026, 13:51David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
-
Apr 11, 2026, 13:47Samrawit Terefe: O Negative Blood Is the Universal Donor With Extreme Scarcity
-
Apr 11, 2026, 13:39Dheeraj Garg: Rethinking Cardiovascular Disease – A Cardiologist’s Perspective
-
Apr 11, 2026, 13:37Kushal Bhatia: Is The 4.5-Hour Thrombolysis Window Officially Outdated?
-
Apr 11, 2026, 13:35William Aird: Why Did Mammalian Red Blood Cells Give Up Their Nucleus?
-
Apr 11, 2026, 13:30Ken Kuang: Gravity Is Constant, But Your Vein Health Doesn’t Have to Be
-
Apr 11, 2026, 13:21Mascha Kern: Measuring Gender’s Role in Stroke and Migraine
-
Apr 11, 2026, 13:10Danique Steeghs: Key Findings from a Microfluidic Chemiluminescent Thrombin Generation Assay
-
Apr 11, 2026, 13:06Shanvi Mahi: A Validated Tool to Explore Lived Experiences After Stroke Rehabilitation